Blog

  • Taylor’s Story For Breast Cancer Awareness Month: A Family Connection That Led to Empowerment

    Taylor’s Story For Breast Cancer Awareness Month: A Family Connection That Led to Empowerment

    During a family reunion on her dad’s side, Taylor found herself learning more than just names and faces: she uncovered a health pattern that would change her life. Several of her cousins had experienced breast cancer, and her paternal grandfather had battled pancreatic cancer. Concerned about what this might mean for her own health, she brought up her family history at her next doctor’s appointment.

    Her physician recommended genetic testing to evaluate her risk for hereditary cancer and chose Otogenetics for its trusted reputation in precision diagnostics. Using the GxVISION Hereditary Cancer Risk Assessment, Otogenetics screened for mutations in genes linked to a range of inherited cancers.

    The results confirmed that Taylor carries a BRCA2 mutation, which significantly increases her risk for breast and ovarian cancers. While the news was difficult to process at first, Otogenetics’ clear reporting and genetic counseling support helped her understand exactly what the results meant and what she could do next. She was quickly referred to a specialist, and together they created a personalized plan for screening and prevention.

    Thanks to early insights from Otogenetics, Taylor feels empowered—not only to take control of her own health but also to make informed decisions about her future. Today, she’s more proactive, more confident, and more connected than ever, having found both medical guidance and emotional support through a local BRCA community group.

    With Otogenetics, Taylor didn’t just get a test—she got a head start.

  • Real Stories: How Otogenetics’ Carrier Screening Changes Lives

    Real Stories: How Otogenetics’ Carrier Screening Changes Lives

    Real Stories: How Otogenetics’ Carrier Screening Changes Lives
    (*Patient names have been changed to protect privacy*)

    The new Carrier Screening standard set by Otogenetics helps Newborn Screening for Early Intervention

    Hearing loss is the most common congenital condition, more than all other common congenital conditions combined. Sarah and Mark knew the challenges of congenital hearing loss—thire first child failed newborn hearing screening and had already been through multiple tests with no avail of the cause(s). Before their second child, Emily, was born, they underwent Otogenetics’ GxVISION carrier screening and learned they were both carriers for GJB2, the most common deafness gene. The carrier screening results revealed what could have caused deafness in their first child and a followup test with Otogenetics of the child confirmed the genetic cause. When Emily was born, testing confirmed she had also inherited the mutations from both parents, which accounts for her failure in newborn hearing screening, relieved the family from multiple hospital visits and tests that may not give them definitive answers.

    With early detection Sarah and Mark were able to connect with an audiologist immediately, ensuring Emily had access to early intervention services prelingually that is critical for her speech and language development.

    Carrier Screening Uncovers Hidden Risks

    Lena had no family history of hearing loss, but when she and her partner underwent genetic screening, they discovered critical information: Lena was a GJB2 carrier, and her partner had two known pathogenic mutations. This meant their child had up to a 50% chance of inheriting hearing loss.

    With this knowledge, they planned for newborn hearing screening and postnatal audiology assessments. Knowing what to expect gave them peace of mind and helped them prepare for the possibility of early intervention if needed.

    Closing the Gaps in Carrier Screening for Precision Care of Families

    Otogenetics is committed to advancing prenatal and newborn genetic testing, ensuring that families and providers have access to the most comprehensive and actionable genetic insights available. Otogenetics Carrier screening includes options that are critical for the common congenital conditions, such as GJB2-linked hearing loss, to benefit the patients. Early, actionable genetic insights allow parents and healthcare providers to collaborate on personalized care plans, ensuring the best possible outcomes for newborns.
    With cutting-edge genetic screening, families like Sarah’s and Lena’s can move forward with confidence—knowing they have the knowledge, resources, and support they need.
    To learn more about how Otogenetics’ advanced GxVISION carrier screening (and comprehensive congenital hearing loss test) can support your family, talk to your doctor or visit www.otogenetics.com.

  • Hiding in Plain Sight: What Genetic Testing Adds to the Diagnosis and Management of Lipid Disorders

    Hiding in Plain Sight: What Genetic Testing Adds to the Diagnosis and Management of Lipid Disorders

    Medical Director of the Lipid Clinic NYU on Genetic Risk Informing Treatment

    James Underberg, MS, MD, FACPM, FACP, FNLA. Dr. James Underberg is Medical Director of the lipid clinic at Bellevue Hospital, Assistant Professor, NYU Grossman School of Medicine. Past President of the National Lipid Association, and a leader in clinical lipidology.

    In the webinar, Dr. Underberg discusses:

    Genetic causes of dyslipidemias including hypercholesterolemia, hypertriglyceridemia, elevated Lp(a)

    • When to use genetic analysis
    • Using genetic analysis to differentially diagnose lipid disorders
    • How genetic risk informs treatment
  • Employing genetics-informed management of Severe Hypertriglyceridemia (SHTG)

    Employing genetics-informed management of Severe Hypertriglyceridemia (SHTG)

    Chief of Cardiology Baylor College of Medicine on Genetics-Informed Management of Severe Hypertriglyceridemia

    Presented by Christie M. Ballantyne, MD, FACC, FAHA. Dr. Christie M. Ballantyne is the Chief of Cardiology, Director of the Center for Cardiometabolic Disease Prevention and Professor of Medicine and Human Genetics at the Baylor College of Medicine. Dr. Ballantyne has co-authored 900 peer-reviewed articles and textbooks on clinical lipidology and cardiovascular disease prevention and management. Dr. Ballantyne is globally recognized lecturer on the molecular genetics and medical management of cardiometabolic diseases.

    In the Webinar, Dr. Ballantyne explores:

    • Genetic architecture of severe hypertriglyceridemia (SHTG)
    • The clinical utility of genetic testing in your patients with SHTG
    • Employing genetics-informed management of your patients with SHTG
  • Using Genetics To Achieve Better Patient Outcomes In Lipid Management

    Using Genetics To Achieve Better Patient Outcomes In Lipid Management

    Heart-to-Heart Webinar by Boston Heart on Genetics and Better Patient Outcomes

    Tara Dall, MD, FNLA*, Dr. Tara Dall is a third-generation primary care physician following in the footsteps of her father, Dr. James Dall and grandfather Dr. Glenn Dall. A graduate of The University of Wisconsin Madison medical school, Dr. Dall is board certified in clinical lipidology with focus on cardiometabolic disease since 2005. She has served as associate clinical professor at the Medical College of Wisconsin as well as a clinical preceptor for the Waukesha family practice residency program to provide a lipid clinic experience for medical trainees.

    In the Webinar, Dr. Dall presents compelling case studies that showcase the synergy between lipid assessments and genetics for optimizing patient outcomes.

  • Personalized Lipidology: Utilize Genomic Testing to Diagnose and Better Manage Lipid Disorders

    Personalized Lipidology: Utilize Genomic Testing to Diagnose and Better Manage Lipid Disorders

    Director of Lipid Clinic University of Chicago on Using Genetics to Tailor Precision Therapeutics

    Michael H. Davidson, MD, FACC, FNLA, is the Director of the Lipid Clinic and Professor of Medicine at the University of Chicago, Pritzker School of Medicine. He is past president of the National Lipid Association (NLA). Dr. Davidson is a nationally recognized expert on lipid-lowering medicines and the reduction of coronary artery disease risk. Dr. Davidson has co-authored over 300 scholarly articles and books on lipid disorders, nutrition, and atherosclerosis and has coordinated more than 1,000 clinical trials in the preventive cardiology space.

    Presented by Dr. Michael H. Davidson*, a leading voice in preventive cardiology.

    Dr. Davidson demonstrates:

    • The clinical utility of genetic testing in your patients
    • When to use genetic testing for diagnosis
    • How to use genetics to tailor precision therapeutics to your patients